Changes in emotions related to medication used to treat ADHD. Part II: Clinical approaches

Robert L Findling, Matthew Brams, Ann C. Childress, Frank A. López, Michael J. Manos, Peter S. Jensen

Research output: Contribution to journalArticle

Abstract

ADHD is one of the most common neurobehavioral disorders of childhood, and FDA-approved medications offer an efficacious treatment option. However, case reports and anecdotal sources suggest that children can have emotional responses, both salutary and detrimental, to these agents. We have previously conducted a comprehensive literature review and found very few research studies systematically examining changes in emotional expression (EE) associated with ADHD medication use. In addition, no empirical data pertaining to the management of these responses could be found. Although few methodologically stringent data are available for changes in EE, such changes should be recognized and measured to determine appropriate responses by clinicians and to maximize treatment benefits and reduce side effects. In this companion report, we draw on available research evidence and clinical experience to explore typical clinical manifestations, differential diagnosis, scales for monitoring, and management approaches of EE observed with pharmacologic treatment of ADHD. In the future, controlled clinical trials of ADHD pharmacotherapy should employ standardized ratings of EE at baseline, during and after treatment. In addition, future research studies should examine various management approaches of these EE changes, to ensure maximal treatment benefits and minimal risks to patients with ADHD who are treated with medication. (J. of Att. Dis. 2011; 15(2) 113-121).

Original languageEnglish (US)
Pages (from-to)113-121
Number of pages9
JournalJournal of Attention Disorders
Volume15
Issue number2
DOIs
StatePublished - Feb 2011
Externally publishedYes

Fingerprint

Emotions
Therapeutics
Controlled Clinical Trials
Research
Differential Diagnosis
Drug Therapy

Keywords

  • ADHD
  • emotional expression
  • stimulants

ASJC Scopus subject areas

  • Clinical Psychology
  • Developmental and Educational Psychology

Cite this

Changes in emotions related to medication used to treat ADHD. Part II : Clinical approaches. / Findling, Robert L; Brams, Matthew; Childress, Ann C.; López, Frank A.; Manos, Michael J.; Jensen, Peter S.

In: Journal of Attention Disorders, Vol. 15, No. 2, 02.2011, p. 113-121.

Research output: Contribution to journalArticle

Findling, Robert L ; Brams, Matthew ; Childress, Ann C. ; López, Frank A. ; Manos, Michael J. ; Jensen, Peter S. / Changes in emotions related to medication used to treat ADHD. Part II : Clinical approaches. In: Journal of Attention Disorders. 2011 ; Vol. 15, No. 2. pp. 113-121.
@article{1e170723fc5941dfb38c4b1757058ecf,
title = "Changes in emotions related to medication used to treat ADHD. Part II: Clinical approaches",
abstract = "ADHD is one of the most common neurobehavioral disorders of childhood, and FDA-approved medications offer an efficacious treatment option. However, case reports and anecdotal sources suggest that children can have emotional responses, both salutary and detrimental, to these agents. We have previously conducted a comprehensive literature review and found very few research studies systematically examining changes in emotional expression (EE) associated with ADHD medication use. In addition, no empirical data pertaining to the management of these responses could be found. Although few methodologically stringent data are available for changes in EE, such changes should be recognized and measured to determine appropriate responses by clinicians and to maximize treatment benefits and reduce side effects. In this companion report, we draw on available research evidence and clinical experience to explore typical clinical manifestations, differential diagnosis, scales for monitoring, and management approaches of EE observed with pharmacologic treatment of ADHD. In the future, controlled clinical trials of ADHD pharmacotherapy should employ standardized ratings of EE at baseline, during and after treatment. In addition, future research studies should examine various management approaches of these EE changes, to ensure maximal treatment benefits and minimal risks to patients with ADHD who are treated with medication. (J. of Att. Dis. 2011; 15(2) 113-121).",
keywords = "ADHD, emotional expression, stimulants",
author = "Findling, {Robert L} and Matthew Brams and Childress, {Ann C.} and L{\'o}pez, {Frank A.} and Manos, {Michael J.} and Jensen, {Peter S.}",
year = "2011",
month = "2",
doi = "10.1177/1087054710381232",
language = "English (US)",
volume = "15",
pages = "113--121",
journal = "Journal of Attention Disorders",
issn = "1087-0547",
publisher = "SAGE Publications Inc.",
number = "2",

}

TY - JOUR

T1 - Changes in emotions related to medication used to treat ADHD. Part II

T2 - Clinical approaches

AU - Findling, Robert L

AU - Brams, Matthew

AU - Childress, Ann C.

AU - López, Frank A.

AU - Manos, Michael J.

AU - Jensen, Peter S.

PY - 2011/2

Y1 - 2011/2

N2 - ADHD is one of the most common neurobehavioral disorders of childhood, and FDA-approved medications offer an efficacious treatment option. However, case reports and anecdotal sources suggest that children can have emotional responses, both salutary and detrimental, to these agents. We have previously conducted a comprehensive literature review and found very few research studies systematically examining changes in emotional expression (EE) associated with ADHD medication use. In addition, no empirical data pertaining to the management of these responses could be found. Although few methodologically stringent data are available for changes in EE, such changes should be recognized and measured to determine appropriate responses by clinicians and to maximize treatment benefits and reduce side effects. In this companion report, we draw on available research evidence and clinical experience to explore typical clinical manifestations, differential diagnosis, scales for monitoring, and management approaches of EE observed with pharmacologic treatment of ADHD. In the future, controlled clinical trials of ADHD pharmacotherapy should employ standardized ratings of EE at baseline, during and after treatment. In addition, future research studies should examine various management approaches of these EE changes, to ensure maximal treatment benefits and minimal risks to patients with ADHD who are treated with medication. (J. of Att. Dis. 2011; 15(2) 113-121).

AB - ADHD is one of the most common neurobehavioral disorders of childhood, and FDA-approved medications offer an efficacious treatment option. However, case reports and anecdotal sources suggest that children can have emotional responses, both salutary and detrimental, to these agents. We have previously conducted a comprehensive literature review and found very few research studies systematically examining changes in emotional expression (EE) associated with ADHD medication use. In addition, no empirical data pertaining to the management of these responses could be found. Although few methodologically stringent data are available for changes in EE, such changes should be recognized and measured to determine appropriate responses by clinicians and to maximize treatment benefits and reduce side effects. In this companion report, we draw on available research evidence and clinical experience to explore typical clinical manifestations, differential diagnosis, scales for monitoring, and management approaches of EE observed with pharmacologic treatment of ADHD. In the future, controlled clinical trials of ADHD pharmacotherapy should employ standardized ratings of EE at baseline, during and after treatment. In addition, future research studies should examine various management approaches of these EE changes, to ensure maximal treatment benefits and minimal risks to patients with ADHD who are treated with medication. (J. of Att. Dis. 2011; 15(2) 113-121).

KW - ADHD

KW - emotional expression

KW - stimulants

UR - http://www.scopus.com/inward/record.url?scp=79551635497&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79551635497&partnerID=8YFLogxK

U2 - 10.1177/1087054710381232

DO - 10.1177/1087054710381232

M3 - Article

C2 - 20858786

AN - SCOPUS:79551635497

VL - 15

SP - 113

EP - 121

JO - Journal of Attention Disorders

JF - Journal of Attention Disorders

SN - 1087-0547

IS - 2

ER -